Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Equity Income (2022 - 2024)

Historic Equity Income for Crinetics Pharmaceuticals (CRNX) over the last 3 years, with Q1 2024 value amounting to -$470000.0.

  • Crinetics Pharmaceuticals' Equity Income changed N/A to -$470000.0 in Q1 2024 from the same period last year, while for Dec 2024 it was -$470000.0, marking a year-over-year increase of 9095.81%. This contributed to the annual value of -$470000.0 for FY2024, which is 9095.81% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Equity Income of -$470000.0 as of Q1 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Equity Income peaked at -$470000.0 during Q1 2024, and registered a low of -$4.2 million during Q4 2023.
  • For the 3-year period, Crinetics Pharmaceuticals' Equity Income averaged around -$1.7 million, with its median value being -$1.0 million (2022).